Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2019 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update

WATERTOWN, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
March 06, 2019 16:01 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Cowen Annual Health Care Conference March 13, 2019

WATERTOWN, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
January 23, 2019 09:19 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Pricing of Public Offering of Common Stock

WATERTOWN, Mass., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
January 22, 2019 16:01 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic...
January 03, 2019 16:11 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D.

Reported completion of SEL-212 Phase 2 study with positive efficacy and tolerability results observed in the clinical trial, in addition to monthly dosing, indicating potential to serve unmet need for...
December 03, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces New Employment Inducement Grants

WATERTOWN, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
November 08, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Prioritized head-to-head superiority clinical trial of SEL-212 compared to Krystexxa, expected to begin in the first quarter of 2019 as part of overall planned Phase 3 clinical development program...
November 06, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Stifel Healthcare Conference 2018

WATERTOWN, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
November 01, 2018 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Report Third Quarter 2018 Financial Results and Update on SEL-212 Development Strategy, including Planned Head-to-Head Study versus Krystexxa

WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
October 23, 2018 07:05 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018

Interim analysis indicates serum uric acid (SUA) control has been maintained into months four and five with once monthly combination treatment, SUA control projected to be 66% at end of study...